ATHA Logo

Athira Pharma, Inc. (ATHA) 

NASDAQ
Market Cap
$27.56M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
87 of 776
Rank in Industry
62 of 433

Largest Insider Buys in Sector

ATHA Stock Price History Chart

ATHA Stock Performance

About Athira Pharma, Inc.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including …

Insider Activity of Athira Pharma, Inc.

Over the last 12 months, insiders at Athira Pharma, Inc. have bought $1.56M and sold $46,454 worth of Athira Pharma, Inc. stock.

On average, over the past 5 years, insiders at Athira Pharma, Inc. have bought $22.92M and sold $36,925 worth of stock each year.

Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC () — $21.94M. Romano Kelly A (director) — $100,051.

The last purchase of 27,400 shares for transaction amount of $66,179 was made by Romano Kelly A (director) on 2024‑06‑24.

List of Insider Buy and Sell Transactions, Athira Pharma, Inc.

2024-09-05SalePresident and CEO
5,032
0.0132%
$0.57$2,848-20.07%
2024-09-05SaleCFO and Chief Business Officer
1,272
0.0033%
$0.57$720-20.07%
2024-09-05SaleCHIEF SCIENTIFIC OFFICER
2,525
0.0066%
$0.57$1,429-20.07%
2024-09-05SaleGENERAL COUNSEL
2,525
0.0066%
$0.57$1,429-20.07%
2024-09-05SaleCOO and CDO
2,525
0.0066%
$0.57$1,429-20.07%
2024-06-24Purchasedirector
27,400
0.0729%
$2.42$66,179-75.36%
2024-06-21Purchasedirector
15,000
0.0347%
$2.26$33,872-74.11%
2024-01-05SaleChief Executive Officer
4,820
0.0129%
$2.91$14,026-11.15%
2024-01-05SaleCFO AND CHIEF BUSINESS OFFICER
1,208
0.0032%
$2.91$3,515-11.15%
2024-01-05SaleCHIEF SCIENTIFIC OFFICER
2,412
0.0065%
$2.91$7,019-11.15%
2024-01-05SaleGeneral Counsel
2,412
0.0065%
$2.91$7,019-11.15%
2024-01-05SaleChief Operating Officer
2,412
0.0065%
$2.91$7,019-11.15%
2023-12-29Purchase
163,954
0.4272%
$2.38$390,211+6.46%
2023-12-28Purchase
409,598
1.0852%
$2.44$999,419+4.08%
2023-12-27Purchase
32,134
0.0833%
$2.28$73,266+10.87%
2023-06-07PurchaseSee Below
15,000
0.0378%
$3.43$51,445-29.80%
2023-06-05PurchaseSee Below
45,000
0.1184%
$3.00$135,150-16.28%
2023-06-02PurchaseSee Below
20,012
0.0493%
$2.82$56,422-16.56%
2023-03-30Purchasedirector
15,000
0.0397%
$2.47$37,050+10.16%
2023-03-29Purchasedirector
10,000
0.0259%
$2.33$23,300+14.13%

Insider Historical Profitability

<0.0001%
PERCEPTIVE ADVISORS LLC
5402964
14.0558%
$0.7250<0.0001%
Gengos AndrewCFO and Chief Business Officer
97532
0.2537%
$0.7233<0.0001%
Romano Kelly Adirector
80715
0.21%
$0.7240<0.0001%
EDELMAN JOSEPH
3695916
9.6149%
$0.7220+8.83%
RTW INVESTMENTS, LP10 percent owner
2668913
6.9432%
$0.7210+9%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Perceptive Advisors$14.8M14.15.4M0%+$00.01
Baker Bros Advisors LP$8.64M8.233.15M0%+$00.06
The Vanguard Group$4.48M4.261.63M-3.77%-$175,414.82<0.0001
Simplify Asset Management Inc$4.09M3.91.49M0%+$00.39
Bml Capital Management Llc$2.47M2.35900,000-38.12%-$1.52M1.89
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.